Asphyxia NeonatorumNeoSupraNCT03133572
Neonatal Resuscitation With Supraglottic Airway Trial
A study testing Supraglottic airway and Face-mask in people with Asphyxia Neonatorum, run by Centre For International Health at 1 site in Uganda.
Trial summary
Mortality rates from birth asphyxia in low-income countries remain very high. Face mask ventilation (FMV) is the most common method of resuscitating neonates in such settings. It is mostly performed by midwives but may not always be satisfactory. Read more about this study
- Who is it for?
- Ages Up to 10 minutes
- Conditions the study is for
- Asphyxia Neonatorum
- What is being tested?
- Supraglottic airway and Face-mask
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,163 participants
- Where
- 1 siteUganda
- Study dates
- 8 May 2018to Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 10 minutes
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Inborn baby (=born in the hospital)
- Expected ≥ 34-week gestation
- Expected birth weight ≥ 2000 g
- Need for PPV at birth
- Parental consent
Who cannot join
- Major malformations (incompatible with sustained life or affecting the airways)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Neonatal Supraglottic Airway Trial: A Single-centre, Open-label, Randomized Clinical Trial to Evaluate the Efficacy of I-gel® Supraglottic Airway Used in Neonatal Resuscitation in Reducing Early Neonatal Mortality and Morbidity
Mortality rates from birth asphyxia in low-income countries remain very high. Face mask ventilation (FMV) is the most common method of resuscitating neonates in such settings. It is mostly performed by midwives but may not always be satisfactory. The i-gel® is a cuffless supraglottic airway which is easy to insert and provides an efficient seal that prevents air leakage with the potential to enhance the performance of neonatal resuscitation. Midwives can be trained in a short time to use this method. A pilot study in Uganda has demonstrated that midwives can safely perform resuscitation of newborn with the i-gel.
OBJECTIVE To investigate whether the use of a cuffless supraglottic airway compared to face-mask ventilation during neonatal resuscitation can reduce early neonatal death (before 7 days of life) or morbidity in neonatal encephalopathy (NE) in asphyxiated neonates.
Read more
STUDY DESIGN, SETTING AND POPULATION A single-centre randomized clinical trial will be conducted at Mulago National Referral Hospital, Kampala, Uganda, among asphyxiated neonates in the delivery units. Prior to the intervention, all staff in the labour ward performing resuscitation will receive training according to the HBB curriculum with a special module for training on supraglottic airway insertion. Resuscitation will be performed according to international guidelines.
UTILITY OF THE STUDY It is crucial to explore alternative, cost-effective modalities that not only would reduce mortality, but also the burden of neurological damage in survivors.
Read the detailed description
One of the targets in the SDG-3 is to reduce neonatal mortality to less than 12 per 1000 live births by 2030. This will require considerable effort in many low-income countries. Perinatal mortality contributes to 40% of infant mortality in Uganda. Early neonatal death from birth asphyxia (BA) could be as high 60%. New evidence-based strategies are needed to reduce mortality from BA in order to achieve SDG-3 by 2030.
Optimal care of the depressed newborn is crucial to prevent and manage BA. The challenge in low-income settings is that highly qualified staff is not readily available to attend to the newborn who require their expertise. In most cases, the midwives are the most skilled personal attending to deliveries and also responsible for resuscitating newborns. At present in low-income settings, FMV is the commonly used method for resuscitating depressed newborn. Easy-to-use equipment such as a supraglottic airway could contribute to obtain more effective ventilation, and improve the outcome of the infant.
This trial is based on a previous pilot trial ClinicalTrials.gov Identifier: NCT02042118.
Primary objective
- To assess if the proportion of either early neonatal death or neonatal encephalopathy (admission to NICU with a Thompson score of 11 or above in day 1-5 during hospitalisation), can be decreased from 40 % in the control arm (using FM) to 30 % or less in the intervention arm (using i-gel supraglottic airway), a 25% decrease.
Secondary objectives
- To assess the safety of a supraglottic airway in the hands of lower cadre (non-doctor) birth attendants in Africa.
- To assess if the proportion of very early and early neonatal deaths is lower in the intervention arm compared to the control arm.
- To assess if the proportion of neonatal encephalopathy (admission to NICU with maximum Thompson score 11 or above), is lower in the intervention arm compared to the control arm.
- To assess if the proportion of neonatal encephalopathy (admission to Neonatal Intensive Care Unit - NICU - with maximum Thompson score 7 or above), is lower in the intervention arm compared to the control arm.
- To assess if hospital admission rate in the first 7 days of life is lower in the intervention arm compared to the control arm.
- To assess the need of advanced resuscitation in the intervention arm compared to the control arm.
Study justification and significance
Training midwives and other birth-attendants can save lives. However, delivering effective positive pressure ventilation (PPV) with FM is a delicate task that requires continuous (re)training. In a previous phase II trial (NCT02042118), it has been shown that a supraglottic airway is safe to use, even in the hands of midwives and with the potential to deliver efficient PPV and perhaps even improve outcome of asphyxiated babies. The cuffless i-gel is simple to use and could therefore be the ideal device to resuscitate newborn when experienced physicians are not available.
Prior to interventions: training midwives in neonatal resuscitation skills
Helping Babies Breathe (HBB) is an evidence-based educational program to teach neonatal resuscitation techniques in resource-limited areas. It is an initiative of the American Academy of Pediatrics (AAP) in collaboration with the World Health Organization (WHO), US Agency for International Development (USAID), Saving Newborn Lives, the National Institute of Child Health and Development, and a number of other global health organizations.
The objective of HBB is to train birth attendants in developing countries in the essential skills of newborn resuscitation, with the goal of having at least one person who is skilled in neonatal resuscitation at the birth of every baby.
The second edition of HBB is now available and will be used in the training.
Study procedures
It is estimated that around 5-10 % of babies born will need ventilation as part of the resuscitation. This randomized trial will include all babies eligible for resuscitation. All newborns in need of resuscitation will be randomized to receive initial treatment using either:
- Supraglottic airway (intervention arm) or
- Face mask (active comparator arm).
The midwife will immediately move the babies not responding to stimulation to the resuscitation area. Ventilation with supraglottic airway or face mask will be initiated immediately. Apgar score and admission to the neonatal ward will be recorded by a research assistant. The intervention may be recorded on video to ensure quality assurance and data collection.
If the infant is hospitalised, daily assessment of Thompson score will be made by a skilled paediatrician/physician. A follow-up visit on day 7 (or later) will determine the outcome (if the infant is alive or not) together with the assessments of Thompson score.
- Conditions
- Asphyxia Neonatorum
- Being tested
- Supraglottic airway, Face-mask
- Medical subject headings
- Asphyxia Neonatorum
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Supraglottic airwayDevice
Also called i-gel, supraglottic airway device
Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
Face-maskDevice
In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
| Study group | Role | What they receive |
|---|---|---|
| Supraglottic airway | Experimental | All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag. Receives: Device: Supraglottic airway |
| Face-mask | Active comparator | All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag. Receives: Device: Face-mask |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite outcome of either a) early neonatal death or b) neonatal encephalopathy
A composite outcome of a) early neonatal death (within 7 days) b) neonatal encephalopathy (admission to NICU with a Thompson score of 11 or above in day 1-5 during hospitalisation).
Measured: Day 7 of life
Secondary outcomes (7)
Number of adverse events (AEs) and serious adverse events (SAEs)
Safety of i-gel in the hands of non-doctor birth attendants (AEs and SAEs)
Measured: Day 7 of life
Early neonatal death
Early neonatal death (within 7 days)
Measured: Day 7 of life
Very early neonatal death
Very early neonatal death (within 24 hours)
Measured: Day 1 of life
Neonatal encephalopathy
Neonatal encephalopathy (admission to NICU with a Thompson score of 11 or above in day 1-5 during hospitalisation).
Measured: Day 7 of life
Mild neonatal encephalopathy
Neonatal encephalopathy (admission to NICU with a Thompson score of 7 or above in day 1-5 during hospitalisation).
Measured: Day 7 of life
Any hospital admission
Any hospital admission
Measured: Day 7 of life
Advanced resuscitation
Advanced resuscitation including intervention by supervising physician
Measured: Day 7 of life
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2017
- Study start8 May 2018
- Primary completion12 Aug 2019
- Study completionDec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Asphyxia NeonatorumStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Day by day, infants will be randomized to either of the arms.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 1,163 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre For International Health
- Sponsor type
- University, hospital or other
- Collaborators
- Makerere University, University of Padova, Karolinska Institutet, Doctors with Africa - CUAMM
- Responsible party
- Sponsor
- Investigators
- Thorkild Tylleskär, MD, PhD, Principal investigator, University of Bergen, Norway
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03133572
- Sponsor's protocol ID
- NeoSupra
- Acronym
- NeoSupra
- Status last verified
- Jun 2020
- First submitted
- 26 Apr 2017
- Last updated
- 29 Jun 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pejovic NJ, Trevisanuto D, Nankunda J, Tylleskar T. Pilot manikin study showed that a supraglottic airway device improved simulated neonatal ventilation in a low-resource setting. Acta Paediatr. 2016 Dec;105(12):1440-1443. doi: 10.1111/apa.13565.
PubMed 27582031Pejovic NJ, Trevisanuto D, Lubulwa C, Myrnerts Hook S, Cavallin F, Byamugisha J, Nankunda J, Tylleskar T. Neonatal resuscitation using a laryngeal mask airway: a randomised trial in Uganda. Arch Dis Child. 2018 Mar;103(3):255-260. doi: 10.1136/archdischild-2017-312934. Epub 2017 Sep 14.
PubMed 28912163Pejovic NJ, Myrnerts Hook S, Byamugisha J, Alfven T, Lubulwa C, Cavallin F, Nankunda J, Ersdal H, Segafredo G, Blennow M, Trevisanuto D, Tylleskar T. Neonatal resuscitation using a supraglottic airway device for improved mortality and morbidity outcomes in a low-income country: study protocol for a randomized trial. Trials. 2019 Jul 19;20(1):444. doi: 10.1186/s13063-019-3455-8.
PubMed 31324213Larsson M, Myrnerts Hook S, Mpamize A, Tylleskar T, Lubulwa C, Trevisanuto D, Elfving K, Pejovic NJ. Oxygen saturation after birth in resuscitated neonates in Uganda: a video-based observational study. BMJ Paediatr Open. 2022 Jan;6(1):e001225. doi: 10.1136/bmjpo-2021-001225.
PubMed 35258476Pejovic NJ, Myrnerts Hook S, Byamugisha J, Alfven T, Lubulwa C, Cavallin F, Nankunda J, Ersdal H, Blennow M, Trevisanuto D, Tylleskar T. A Randomized Trial of Laryngeal Mask Airway in Neonatal Resuscitation. N Engl J Med. 2020 Nov 26;383(22):2138-2147. doi: 10.1056/NEJMoa2005333.
PubMed 33252870
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neonatal Supraglottic Airway Trial: A Single-centre, Open-label, Randomized Clinical Trial to Evaluate the Efficacy of I-gel® Supraglottic Airway Used in Neonatal Resuscitation in Reducing Early Neonatal Mortality and Morbidity
- ClinicalTrials.gov ID
- NCT03133572
- Acronym / sponsor ID
- NeoSupra / NeoSupra
- Conditions
- Asphyxia Neonatorum
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,163 participants (actual)
- Lead sponsor
- Centre For International HealthUniversity, hospital or other
- Collaborators
- Makerere University, University of Padova, Karolinska Institutet, Doctors with Africa - CUAMM
- Study start
- 8 May 2018 (actual)
- Primary completion
- 12 Aug 2019 (actual)
- Study completion
- Dec 2021 (estimated)
- First posted
- 28 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mortality rates from birth asphyxia in low-income countries remain very high. Face mask ventilation (FMV) is the most common method of resuscitating neonates in such settings. It is mostly performed by midwives but may not always be satisfactory. The i-gel® is a cuffless supraglottic airway which is easy to insert and provides an efficient seal that prevents air leakage with the potential to enhance the performance of neonatal resuscitation. Midwives can be trained in a short time to use this method. A pilot study in Uganda has demonstrated that midwives can safely perform resuscitation of newborn with the i-gel.
OBJECTIVE To investigate whether the use of a cuffless supraglottic airway compared to face-mask ventilation during neonatal resuscitation can reduce early neonatal death (before 7 days of life) or morbidity in neonatal encephalopathy (NE) in asphyxiated neonates.
STUDY DESIGN, SETTING AND POPULATION A single-centre randomized clinical trial will be conducted at Mulago National Referral Hospital, Kampala, Uganda, among asphyxiated neonates in the delivery units. Prior to the intervention, all staff in the labour ward performing resuscitation will receive training according to the HBB curriculum with a special module for training on supraglottic airway insertion. Resuscitation will be performed according to international guidelines.
UTILITY OF THE STUDY It is crucial to explore alternative, cost-effective modalities that not only would reduce mortality, but also the burden of neurological damage in survivors.
Detailed description
One of the targets in the SDG-3 is to reduce neonatal mortality to less than 12 per 1000 live births by 2030. This will require considerable effort in many low-income countries. Perinatal mortality contributes to 40% of infant mortality in Uganda. Early neonatal death from birth asphyxia (BA) could be as high 60%. New evidence-based strategies are needed to reduce mortality from BA in order to achieve SDG-3 by 2030.
Optimal care of the depressed newborn is crucial to prevent and manage BA. The challenge in low-income settings is that highly qualified staff is not readily available to attend to the newborn who require their expertise. In most cases, the midwives are the most skilled personal attending to deliveries and also responsible for resuscitating newborns. At present in low-income settings, FMV is the commonly used method for resuscitating depressed newborn. Easy-to-use equipment such as a supraglottic airway could contribute to obtain more effective ventilation, and improve the outcome of the infant.
This trial is based on a previous pilot trial ClinicalTrials.gov Identifier: NCT02042118.
Primary objective
- To assess if the proportion of either early neonatal death or neonatal encephalopathy (admission to NICU with a Thompson score of 11 or above in day 1-5 during hospitalisation), can be decreased from 40 % in the control arm (using FM) to 30 % or less in the intervention arm (using i-gel supraglottic airway), a 25% decrease.
Secondary objectives
- To assess the safety of a supraglottic airway in the hands of lower cadre (non-doctor) birth attendants in Africa.
- To assess if the proportion of very early and early neonatal deaths is lower in the intervention arm compared to the control arm.
- To assess if the proportion of neonatal encephalopathy (admission to NICU with maximum Thompson score 11 or above), is lower in the intervention arm compared to the control arm.
- To assess if the proportion of neonatal encephalopathy (admission to Neonatal Intensive Care Unit - NICU - with maximum Thompson score 7 or above), is lower in the intervention arm compared to the control arm.
- To assess if hospital admission rate in the first 7 days of life is lower in the intervention arm compared to the control arm.
- To assess the need of advanced resuscitation in the intervention arm compared to the control arm.
Study justification and significance
Training midwives and other birth-attendants can save lives. However, delivering effective positive pressure ventilation (PPV) with FM is a delicate task that requires continuous (re)training. In a previous phase II trial (NCT02042118), it has been shown that a supraglottic airway is safe to use, even in the hands of midwives and with the potential to deliver efficient PPV and perhaps even improve outcome of asphyxiated babies. The cuffless i-gel is simple to use and could therefore be the ideal device to resuscitate newborn when experienced physicians are not available.
Prior to interventions: training midwives in neonatal resuscitation skills
Helping Babies Breathe (HBB) is an evidence-based educational program to teach neonatal resuscitation techniques in resource-limited areas. It is an initiative of the American Academy of Pediatrics (AAP) in collaboration with the World Health Organization (WHO), US Agency for International Development (USAID), Saving Newborn Lives, the National Institute of Child Health and Development, and a number of other global health organizations.
The objective of HBB is to train birth attendants in developing countries in the essential skills of newborn resuscitation, with the goal of having at least one person who is skilled in neonatal resuscitation at the birth of every baby.
The second edition of HBB is now available and will be used in the training.
Study procedures
It is estimated that around 5-10 % of babies born will need ventilation as part of the resuscitation. This randomized trial will include all babies eligible for resuscitation. All newborns in need of resuscitation will be randomized to receive initial treatment using either:
- Supraglottic airway (intervention arm) or
- Face mask (active comparator arm).
The midwife will immediately move the babies not responding to stimulation to the resuscitation area. Ventilation with supraglottic airway or face mask will be initiated immediately. Apgar score and admission to the neonatal ward will be recorded by a research assistant. The intervention may be recorded on video to ensure quality assurance and data collection.
If the infant is hospitalised, daily assessment of Thompson score will be made by a skilled paediatrician/physician. A follow-up visit on day 7 (or later) will determine the outcome (if the infant is alive or not) together with the assessments of Thompson score.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Day by day, infants will be randomized to either of the arms.
| Arm | Type | Receives |
|---|---|---|
| Supraglottic airway | Experimental | Device: Supraglottic airwayAll newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag. |
| Face-mask | Active comparator | Device: Face-maskAll newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag. |
Who may qualify
- Ages
- Up to 10 minutes
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Inborn baby (=born in the hospital)
- Expected ≥ 34-week gestation
- Expected birth weight ≥ 2000 g
- Need for PPV at birth
- Parental consent
Key exclusion criteria (1 listed)
- Major malformations (incompatible with sustained life or affecting the airways)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Supraglottic airwayAlso: i-gel, supraglottic airway deviceInstead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag. | Device | Supraglottic airway |
| Face-maskIn order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag. | Device | Face-mask |
Primary outcome
Composite outcome of either a) early neonatal death or b) neonatal encephalopathy
Time frame: Day 7 of life
A composite outcome of a) early neonatal death (within 7 days) b) neonatal encephalopathy (admission to NICU with a Thompson score of 11 or above in day 1-5 during hospitalisation).
7 secondary outcomes
Number of adverse events (AEs) and serious adverse events (SAEs)
Time frame: Day 7 of life
Early neonatal death
Time frame: Day 7 of life
Very early neonatal death
Time frame: Day 1 of life
Neonatal encephalopathy
Time frame: Day 7 of life
Mild neonatal encephalopathy
Time frame: Day 7 of life
Any hospital admission
Time frame: Day 7 of life
Advanced resuscitation
Time frame: Day 7 of life
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2020.
- Background: PubMed 27582031Pejovic NJ, Trevisanuto D, Nankunda J, Tylleskar T. Pilot manikin study showed that a supraglottic airway device improved simulated neonatal ventilation in a low-resource setting. Acta Paediatr. 2016 Dec;105(12):1440-1443. doi: 10.1111/apa.13565.
- Background: PubMed 28912163Pejovic NJ, Trevisanuto D, Lubulwa C, Myrnerts Hook S, Cavallin F, Byamugisha J, Nankunda J, Tylleskar T. Neonatal resuscitation using a laryngeal mask airway: a randomised trial in Uganda. Arch Dis Child. 2018 Mar;103(3):255-260. doi: 10.1136/archdischild-2017-312934. Epub 2017 Sep 14.
- Background: PubMed 31324213Pejovic NJ, Myrnerts Hook S, Byamugisha J, Alfven T, Lubulwa C, Cavallin F, Nankunda J, Ersdal H, Segafredo G, Blennow M, Trevisanuto D, Tylleskar T. Neonatal resuscitation using a supraglottic airway device for improved mortality and morbidity outcomes in a low-income country: study protocol for a randomized trial. Trials. 2019 Jul 19;20(1):444. doi: 10.1186/s13063-019-3455-8.
- Derived from this study: PubMed 35258476Larsson M, Myrnerts Hook S, Mpamize A, Tylleskar T, Lubulwa C, Trevisanuto D, Elfving K, Pejovic NJ. Oxygen saturation after birth in resuscitated neonates in Uganda: a video-based observational study. BMJ Paediatr Open. 2022 Jan;6(1):e001225. doi: 10.1136/bmjpo-2021-001225.
- Derived from this study: PubMed 33252870Pejovic NJ, Myrnerts Hook S, Byamugisha J, Alfven T, Lubulwa C, Cavallin F, Nankunda J, Ersdal H, Blennow M, Trevisanuto D, Tylleskar T. A Randomized Trial of Laryngeal Mask Airway in Neonatal Resuscitation. N Engl J Med. 2020 Nov 26;383(22):2138-2147. doi: 10.1056/NEJMoa2005333.
- Individual participant dataSharing planned: No
Related trials for Asphyxia Neonatorum
Recruiting
Sustained Cord Circulation at Emergency Cesarean Section
Asphyxia Neonatorum, Fetal Hypoxia
Not yet recruiting
Levetiracetam as an Adjuvant Therapy to Hypothermia in Neonatal Asphyxia
Hypoxic Ischemic Encephalopathy of Newborn, Neuro-protection
Active, not recruiting
Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants
IVH- Intraventricular Hemorrhage, Extreme Prematurity
Not yet recruiting
Magnesium Sulphate for Neonatal Asphyxia and Length of Hospital Stay
Duration of Hospitalization, Neonatal Mortality Rate
RecruitingPhase 2
Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia
Neonatal Encephalopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thorkild Tylleskär, MD, PhD principal investigator
University of Bergen, Norway
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Supraglottic airway and Face-mask in people with Asphyxia Neonatorum, run by Centre For International Health at 1 site in Uganda.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite outcome of either a) early neonatal death or b) neonatal encephalopathy (time frame: Day 7 of life). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03133572, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2020.